Basics of International Trademark Protection

You have started your new business. Congratulations. At least you have implemented your idea. You are about to skyrocket into the business lion’s den. Your idea is going to take you places. You will become your own boss. You will employ many people. But wait, people can steal your idea and make money out of





Strict Product Liability

Arkansas has long followed the Restatement (Second) of Torts Section 402A (1965) which provides that in order for a plaintiff to recover for harm or injury caused by a defective product, the product must be sold “in a defective condition” and be unreasonably dangerous to a consumer. What this means is that as a consumer, you


Breach of Warranty

When a seller makes a promise to a buyer there are implications if the seller breaks that promise. Breach of warranty is a possible remedy for a buyer if a broken promise has caused them harm.


Weill-Cornell Study Yields Shocking Conclusions Regarding Essure

This equivocates to roughly one out of 49-50 women needing surgery to repair or remove the device. Dr. Sedrakyan also added that the “surgery is likely to be much more complicated than the laproscopic approach that they should be considering. For its part, the FDA has acknowledged the study, releasing a statement saying “This is a high priority issue for the agency. The FDA plans to review the findings of this study, along with the latest medical literature on the Essure device and input from panel members and the public during our recent advisory committee meeting, to determine what future actions may be appropriate.” The FDA has not indicated, however, that it is planning on pulling the device from the market.


FDA Delays Review of Collegium’s Abuse-Deterrent Opioid Xtampza

Despite the dosing concerns, however, the advisory panel voted 23-0 in favor of recommending Xtampza for approval. The FDA generally follows the advice of advisory panels, although it is not obligated to do so. While the FDA stated days prior to the panel meeting that Collegium’s packaging should contain a clearer warning about the dosing issue, it did not explicitly state that approval was contingent on labeling improvements.